BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 15894686)

  • 1. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies.
    Amoura Z; Duhaut P; Huong DL; Wechsler B; Costedoat-Chalumeau N; Francès C; Cacoub P; Papo T; Cormont S; Touitou Y; Grenier P; Valeyre D; Piette JC
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1279-82. PubMed ID: 15894686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis.
    Selva-O'Callaghan A; Grau JM; Gámez-Cenzano C; Vidaller-Palacín A; Martínez-Gómez X; Trallero-Araguás E; Andía-Navarro E; Vilardell-Tarrés M
    Am J Med; 2010 Jun; 123(6):558-62. PubMed ID: 20569766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
    Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
    Li CS; Cheng BC; Ge W; Gao JF
    Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
    Yang XQ; Yan L; Chen C; Hou JX; Li Y
    Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The overall and temporal association of cancer with polymyositis and dermatomyositis.
    Zantos D; Zhang Y; Felson D
    J Rheumatol; 1994 Oct; 21(10):1855-9. PubMed ID: 7837150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting factors of interstitial lung disease in dermatomyositis and polymyositis.
    Chen YJ; Wu CY; Shen JL
    Acta Derm Venereol; 2007; 87(1):33-8. PubMed ID: 17225013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early detection of pancreatic cancer by serum markers].
    Nakae Y; Naruse S; Shibata T; Kitagawa M; Kondo T; Hayakawa T; Kuno N; Kurimoto K
    Rinsho Byori; 1994 Feb; 42(2):139-42. PubMed ID: 7511183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer.
    Fujimura T; Kinami S; Ninomiya I; Kitagawa H; Fushida S; Nishimura G; Kayahara M; Shimizu K; Ohta T; Miwa K
    Endoscopy; 2002 Jul; 34(7):569-74. PubMed ID: 12170412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis.
    Wong RC; Klingberg S; Wilson R
    J Rheumatol; 2002 Sep; 29(9):2021-2; author reply 2022. PubMed ID: 12233905
    [No Abstract]   [Full Text] [Related]  

  • 19. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study.
    András C; Ponyi A; Constantin T; Csiki Z; Szekanecz E; Szodoray P; Dankó K
    J Rheumatol; 2008 Mar; 35(3):438-44. PubMed ID: 18203322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.